F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
1271P 4-year survival in randomised phase II (POPLAR) and phase III (OAK) studies of atezolizumab (atezo) vs docetaxel (doc) in pre-treated NSCLC
Julien Mazieres,Achim Rittmeyer,S. Gadgeel,Toyoaki Hida,David R. Gandara,Diego Cortinovis,Fabrice Barlesi,Wei Yu,C. Matheny,Marcus Ballinger,K. Park +10 more
Journal ArticleDOI
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC
W. Schütte,Fabrice Barlesi,Kwan Park,Fortunato Ciardiello,J. von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,M Cobo Dols,Diego Cortinovis,Joseph W. Leach,J Polikoff,Gandara, DR[Gandara, D. R.],Carlos H. Barrios,Daniel S. Chen,Pei He,Marcus Ballinger,Daniel Waterkamp,Alan Sandler,Achim Rittmeyer +19 more
Posted Content
Oncogenic drivers in daily practice improve overall survival in patients ă with lung adenocarcinoma
C. Fournier,L. Greillier,F. Fina,V. Secq,I. Nanni-Metellus,Anderson Loundou,S. Garcia,L. Ouafik,P. Tomasini,Fabrice Barlesi +9 more
TL;DR: An actionable oncodriver was routinely detected in nearly half of patients with advanced lung adenocarcinoma, and this systematic detection may influence treatment outcomes, notably with matched targeted therapy.
Journal ArticleDOI
Caractéristiques des patients atteints de cancer bronchopulmonaire non à petites cellules (CBNPC) traités par nivolumab en condition de vie réelle : première analyse de l’étude EVIDENS (lung cancer patients treated with nivolumab : a longitudinal, prospective, observational, multicentric study)
Clarisse Audigier-Valette,Maurice Pérol,Fabrice Barlesi,Didier Debieuvre,Jean-Bernard Auliac,P. Bombaron,A. Dixmier,C. Raspaud,E. Nabirotchkina,N. Benoit,B. Asselain,D. Moro-Sibilot +11 more
TL;DR: L’analyse preliminaire d’EVIDENS apporte une description precise of the population traitee en conditions de vie reelle par nivolumab pour un CBNPC avance en France.
Journal Article
OAK, a randomized Ph III study of atezolizumab vs docetaxel in patients with advanced NSCLC: results from subgroup analyses
W. Schütte,S. Gadgeel,Fortunato Ciardiello,Achim Rittmeyer,Fabrice Barlesi,Diego Cortinovis,Carlos H. Barrios,Toyoaki Hida,K. Park,Dariusz M. Kowalski,Manuel Cobo Dols,Joseph W. Leach,Jonathan Polikoff,C. Matheny,Pei He,Marcin Kowanetz,Daniel S. Chen,Daniel Waterkamp,Marcus Ballinger,Alan Sandler,Gandara, DR[Gandara, D. R.],Jmd von Pawel +21 more